active metabolites obvious anticholinergic

currently used in clinical weight loss drugs into two categories: central nervous system the role of diet pills diet pills and the role of non-central nervous system. 3.1 central nervous system the role of diet pills such drugs in the central nervous system, increase anorexia neurotransmitters (norepinephrine, 5-hydroxytryptamine, dopamine) utilization, inhibiting feeding center of appetite. The healing power of meizitang has been recognized vast number of obese people.
Representative drugs: ① The dextral fenfluramine / fenfluramine: heart valve damage, pulmonary hypertension and other serious adverse reactions have been out of the market; ② The sibutramine (Sibutramine is): the role of central obesity treatment drug recommended for the treatment of body mass index> 130kg/m2 or> 27kg/m2 (other obesity in patients with risk factors such as hypertension, diabetes, dyslipidemia, etc.), mainly through its amine (secondary amines and primary amines) metabolites have an effect, its main mechanism for inhibiting norepinephrine and 5 hydroxytryptamine and dopamine reuptake to enhance satiety. The medicalmeizitanghave helped a gathering of people. To solve the problem of obesity, people need effective meizitang.  While promoting muscle, adipose tissue glucose utilization, lower blood sugar, blood lipids, had no significant effect on norepinephrine, serotonin and dopamine release study also showed that this product its amine active metabolites obvious anticholinergic, anti-histamine and monoamine oxidase inhibition. drug does not cause a 5 HT release does not occur with valvular heart disease complications. the recommended dose of sibutramine daily medication 1, a 10mg, taken separately in the morning or taking breakfast at the same time, such as weight loss is not obvious, four weeks after the dose increased to a daily 15mg. Not meet the attitude held by the common in obese patients for weight loss and providing training to prevent relapse in the other weight control programs has been guilty of some common mistakes. three drug treatment drug treatment as part of the obesity long-term treatment strategies can only be an adjunct. It is correct that the value of our meizitang has been recorded.  To diet and exercise to treat obese patients weigh the risk of the continuing risk of obesity and drug treatment, to determine whether drug treatment should be considered when the following conditions exist drug therapy: hunger or appetite, hyperactivity lead weight gain.
Existence of concomitant diseases, including impaired glucose tolerance (IGT), dyslipidemia, and hypertension: the presence of other symptoms of complications, such as severe osteoarthritis, obstructive sleep apnea, reflux esophagitis inflammation and lacunar syndrome.